International Institute for Nanotechnology

Flashpoint Therapeutics Announces $10M Seed Financing Led by Beta Lab to Pioneer Nanotechnology-Enabled Medicines

Retrieved on: 
Wednesday, October 25, 2023
Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Nanotechnology, Biotechnology, Health, Other Science, Trial of the century, Cervical cancer, Therapy, RNA, Hope, Northwestern University, CRISPR, Architecture, Liver, Nokia phones beta labs, General partnership, Flashpoint, Prostate cancer, Cell, Cancer, International Institute for Nanotechnology, Immune system, Breast cancer, Nanostructure, Kinetics, Brain, Melanoma, Glioma, Lymphoma, Pharmaceutical industry, Vaccine

Flashpoint will also use the funds to expand its team and enhance the platform to develop best-in-class multi-targeted RNA, CRISPR and peptide therapeutics with unique characteristics.

Key Points: 
  • Flashpoint will also use the funds to expand its team and enhance the platform to develop best-in-class multi-targeted RNA, CRISPR and peptide therapeutics with unique characteristics.
  • This approach overcomes limitations of current technologies that rely on mixing therapeutic components with little control over their co-delivery or structural presentation.
  • “We are thrilled to announce a $10 million seed financing round led by Beta Lab, a leading deep tech venture capital firm,” said Adam Margolin, Ph.D., CEO & Founder, Flashpoint Therapeutics.
  • Flashpoint plans to partner with leading companies in nucleic acid and peptide therapeutics to develop best-in-class therapeutic candidates in these areas.

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

Retrieved on: 
Tuesday, September 12, 2023
Acceleration, Management development, Human resources, University, IBM, Bachelor, IPO, Engineering, Chief business officer, Culture, Business, MBA, Birla Institute of Technology and Science, Pilani – Dubai Campus, International Institute for Nanotechnology, MS, Treasury, International, Novartis, CBO, Uneek Havana Cigar Company, Roivant Sciences, CFO, Growth, Citibank, Birla Institute of Technology, Mesra, Certified Treasury Professional, Management, Pharmaceutical industry, Science, Oncology, Facility, Electronics

EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.

Key Points: 
  • EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.
  • Mr. Mehra will lead 4DMT’s finance, business development, and precommercial functions and will be a member of 4DMT’s Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • “We are thrilled to welcome Uneek to 4DMT at an important inflection point in our company progress towards pivotal trials across multiple programs,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • As Chief Financial Officer of the US Integrated Care and Critical Care Business Units, Mr. Mehra supported commercial excellence across multiple products; notably, driving the launch and execution of Cosentyx® and Entresto®.

Capital Market Authority: The Kingdom has achieved advanced ranks in indicators related to the financial market

Retrieved on: 
Thursday, June 22, 2023
Private law, Management development, Venture, CMA, National Competitiveness Report of Armenia, Venture capital, IMD, Equity, International Institute for Nanotechnology, International, Authority, G20, Foreign investment, Environment, Renewable energy, Bank, Kingdom

From 2022 to 2023, the Kingdom advanced from 24th to 17th rank, marking a tremendous leap in its global standing.

Key Points: 
  • From 2022 to 2023, the Kingdom advanced from 24th to 17th rank, marking a tremendous leap in its global standing.
  • According to the yearbook, six of the twelve capital market indices showed upward strides while maintaining their positions in two others.
  • This achievement exemplifies the CMA's continued efforts and steps to improve and expand the Kingdom's capital markets by implementing relevant global best practices.
  • The rules will also help transform knowledge and experiences among local capital institutions and investors, strengthening institutional investors' involvement in the Saudi capital market.

I2SL Launches Labs2Zero Program to Help Reduce Energy and Emissions From Research Facilities

Retrieved on: 
Tuesday, April 25, 2023
Biotechnology, Health, General Health, Other Energy, Health Technology, Utilities, Research, Environment, Energy, Science, Sustainability, Laboratory, Carbon, International Institute for Nanotechnology, Engineering, Certification, Climate, Renewable energy, Accreditation

To address this issue, the International Institute for Sustainable Laboratories (I2SL) has launched the Labs2Zero program in cooperation with leading lab experts and sponsor companies to help decarbonize life science facilities.

Key Points: 
  • To address this issue, the International Institute for Sustainable Laboratories (I2SL) has launched the Labs2Zero program in cooperation with leading lab experts and sponsor companies to help decarbonize life science facilities.
  • “Labs2Zero is a major new initiative helping accelerate the decarbonization of the world’s laboratories to dramatically reduce their emissions,” said I2SL President Gordon Sharp.
  • Actionable Insights and Measures Report: Based on their energy and emissions score, labs will receive suggestions for energy and emissions reduction measures and relevant case studies.
  • In addition, contributions from founding sponsors will help fund development of criteria and tools to support the Labs2Zero program components.

Mattiq Launches With Revolutionary Approach to Developing Sustainable Materials

Retrieved on: 
Wednesday, February 8, 2023
Software, Research, Other Energy, Sustainability, Energy, Technology, Artificial Intelligence, Environment, Semiconductor, Science, Nanotechnology, Chemicals, Plastics, Manufacturing, MBA, Biotechnology, Wharton School of the University of Pennsylvania, Cornell University, International Institute for Nanotechnology, Intelligent Systems, Acquisition, Engineering, University, Silicon, Intelligence, Multimedia, General Electric, AI, Renewable energy, Northwestern University

“From the stone age to the silicon era, materials discovery has been slow, unpredictable, and constrained by the performance of available materials,” said Mattiq Founder and Director Chad Mirkin.

Key Points: 
  • “From the stone age to the silicon era, materials discovery has been slow, unpredictable, and constrained by the performance of available materials,” said Mattiq Founder and Director Chad Mirkin.
  • At the same time, this work generates unprecedented amounts of high quality data that is enabling Mattiq to build the world’s most powerful materials AI.
  • Mattiq is a transformative materials design and development company on a mission to decarbonize the fundamental building blocks that power our world.
  • Spun out from Northwestern University, Mattiq blends materials science and artificial intelligence to accelerate the exploration, discovery, and real-world deployment of new materials and processes to power commercially viable, sustainable production of critical chemicals and fuels.

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

Retrieved on: 
Monday, December 5, 2022
Sarcoidosis, Laboratory, Degenerative disease, Idiopathic pulmonary fibrosis, Cell biology, Flemish Institute for Technological Research, University, Rutgers University, Warsaw Stock Exchange, VIB, Yale University, Patient, ARG1, Cancer, Biology, ARG2, International Institute for Nanotechnology, RNA, MOC, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

Retrieved on: 
Monday, December 5, 2022
Sarcoidosis, Laboratory, Degenerative disease, Idiopathic pulmonary fibrosis, Cell biology, Flemish Institute for Technological Research, University, Rutgers University, Warsaw Stock Exchange, VIB, Yale University, Patient, ARG1, Cancer, Biology, ARG2, International Institute for Nanotechnology, RNA, MOC, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Save The Date: Molecure to Host Virtual R&D Day on 7th December 2022

Retrieved on: 
Monday, November 14, 2022
Idiopathic pulmonary fibrosis, Yale University, RNA, International Institute for Nanotechnology, VIB, Sarcoidosis, Biology, University, Cancer, Degenerative disease, Rutgers University, Patient, Warsaw Stock Exchange, MOC, Cell biology, ARG2, Flemish Institute for Technological Research, ARG1, Laboratory, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Save The Date: Molecure to Host Virtual R&D Day on 7th December 2022

Retrieved on: 
Monday, November 14, 2022
Idiopathic pulmonary fibrosis, Yale University, RNA, International Institute for Nanotechnology, VIB, Sarcoidosis, Biology, University, Cancer, Degenerative disease, Rutgers University, Patient, Warsaw Stock Exchange, MOC, Cell biology, ARG2, Flemish Institute for Technological Research, ARG1, Laboratory, Pharmaceutical industry

Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.

Key Points: 
  • Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
  • A Phase II trial in patients with sarcoidosis is expected to start in 2023.
  • Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.
  • Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Toyota Research Institute and Northwestern Join Forces to Accelerate the Discovery of Materials that Will Drive the Clean Energy Transition

Retrieved on: 
Wednesday, August 17, 2022
Carbon, Machine learning, TRI, Atmosphere, Genome, International Institute for Nanotechnology, Algorithm, Robotics, Student, Research, LOS, Iridium, CO2, Partnership, Transport, Nanotechnology, Platinum, Medical device, Northwestern, Chemistry, Northwestern University

LOS ALTOS, Calif. and CHICAGO, Aug. 17, 2022 /PRNewswire/ -- Toyota Research Institute (TRI) and Northwestern University today announce their collaboration to help accelerate new materials discovery, design and development with the world's first nanomaterial "data factory." This AI-driven methodology goes far beyond the traditional trial and error by exploring vast parameter sets, collecting data and then empowering AI to search the materials genome to find the best materials for a given application. While the first application of the data factory will be used to discover new catalysts to make fuel cell vehicles more efficient, TRI and Northwestern believe this method of materials discovery will have wide-ranging applications in the future such as clean hydrogen production, CO2 removal from air and high-efficiency solar cells.

Key Points: 
  • "Meeting the growing demand for mobility without emitting carbon is a major challenge," said Brian Storey , TRI senior director of energy and materials.
  • "Together with TRI, we're poised to empower the scientific community to find the best materials that can truly power the clean energy transition."
  • Toyota Research Institute (TRI) conducts research to advance robotics, energy and materials, machine learning, and human-centric artificial intelligence.
  • Northwestern provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.